Abstract
Data sources The US Food and Drug Administration (FDA), Health Canada, European Medicines Agency (EMA)/European Commission and UK's Medicines and Healthcare products Regulatory Agency (MHRA).
Study selection Product monographs, product information and consumer medicine information for the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines.
Data extraction and synthesis Reported side/adverse/undesirable effects concerning the orofacial region were extracted and tabulated.
Results There were rare reports of adverse events affecting the orofacial region for both vaccines in their pertaining documents, including acute peripheral facial paralysis (Bell's palsy), facial swelling and swelling of the lips, face or tongue associated with anaphylaxis. There was heterogeneity in the acknowledgement of vaccine-related adverse events in North America compared with Europe.
Conclusions There are rare reports of orofacial adverse effects of two mRNA-based COVID-19 vaccines in their documents; however, there are inconsistencies in the description of these adverse effects in different countries.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Butler R, MacDonald N E. Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP). Vaccine 2015; 33: 4176-4179.
Harrison E A, Wu J W. Vaccine confidence in the time of COVID-19. Eur J Epidemiol 2020; 35: 325-330.
Dror A A, Eisenbach N, Taiber S et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol 2020; 35: 775-779.
Greinacher A, Thiele T, Warkentin T E, Weisser K, Kyrle P A, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021; DOI: 10.1056/NEJMoa2104840.
Schultz N H, Sørvoll I H, Michelsen A E et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; DOI: 10.1056/NEJMoa2104882.
Scully M, Singh D, Lown R et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 2021; DOI: 10.1056/NEJMoa2105385.
Muir K L, Kallam A, Koepsell S A, Gundabolu K. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. N Engl J Med 2021; DOI: 10.1056/NEJMc2105869.
Mahase E. AstraZeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. BMJ 2021; DOI: 10.1136/bmj.n931.
Taquet M, Husain M, Geddes J R, Luciano S, Harrison P J. Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine. 2021.
Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. J Oral Pathol Med 2021; 50: 424-427.
Riad A, Koscik M, Attia S, Conrad J, Mekhemar M, Hocková B. Oral Side Effects of COVID-19 Vaccine. 2021. Available at https://clinicaltrials.gov/ct2/show/NCT04706156 (accessed May 2021).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sofi-Mahmudi, A. Orofacial adverse effects of COVID-19 vaccines exist but are rare. Evid Based Dent 22, 70–71 (2021). https://doi.org/10.1038/s41432-021-0178-y
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41432-021-0178-y
